TFF Pharmaceuticals, Inc. (TFFP)
NASDAQ: TFFP · Real-Time Price · USD
0.308
-0.014 (-4.38%)
Dec 3, 2024, 12:26 PM EST - Market open
TFF Pharmaceuticals Employees
TFF Pharmaceuticals had 19 employees as of December 31, 2023. The number of employees increased by 4 or 26.67% compared to the previous year.
Employees
19
Change (1Y)
4
Growth (1Y)
26.67%
Revenue / Employee
$61,116
Profits / Employee
-$974,827
Market Cap
1.35M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| China SXT Pharmaceuticals | 75 |
| TC Biopharm (Holdings) | 41 |
| Helius Medical Technologies | 22 |
| Altamira Therapeutics | 10 |
| Bluejay Diagnostics | 10 |
| PainReform | 7 |
| Aclarion | 6 |
| IMAC Holdings | 4 |
TFFP News
- 18 days ago - TFF Pharmaceuticals Announces It Will Wind Down Operations - GlobeNewsWire
- 2 months ago - TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID - GlobeNewsWire
- 3 months ago - TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization - GlobeNewsWire
- 4 months ago - TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire
- 5 months ago - TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities - GlobeNewsWire
- 6 months ago - TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing - GlobeNewsWire
- 7 months ago - TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing - GlobeNewsWire
- 7 months ago - TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire